Mereo BioPharma Group plc (NASDAQ: MREO) – a clinical-stage biopharmaceutical company focused on rare diseases – is facing intense scrutiny after a catastrophic trial failure wiped out nearly 90% of its stock value and spurred multiple securities class-action lawsuits (www.globenewswire.com). Investors who purchased Mereo’s American Depositary Shares (ADS) between June 5, 2023 and December 26, 2025 are being urged to act: law firms have filed suits alleging that Mereo misled shareholders about its drug prospects, with an important April 6, 2026 lead-plaintiff deadline for affected investors to secure legal counsel (www.globenewswire.com). Below, we deep-dive into Mereo’s current situation – from its dividend policy to financial stability, valuation, and the risks and open questions ahead – to equip investors with a clear picture of the road forward.

Company Background & Legal Alert

Mereo specializes in developing therapeutics for rare diseases, with a pipeline that (until recently) was headlined by setrusumab (an antibody for Osteogenesis Imperfecta, or “brittle bone” disease) and alvelestat (an oral therapy for alpha-1 antitrypsin deficiency lung disease). Throughout 2023–2025, management struck an optimistic tone about setrusumab’s Phase 3 trials (“ORBIT” and “COSMIC”). For instance, just weeks before data readout, CEO Dr. Denise Scots-Knight stated “we remain confident in the potential of setrusumab to reduce fractures and improve quality of life for people with OI” (www.biospace.com), underscoring preparation for a potential launch. According to the class-action complaint, such upbeat statements – expressing “confidence in setrusumab’s ability to ultimately reduce the annualized fracture rates … and succeed in reaching statistical significance” – were materially misleading (www.globenewswire.com). The lawsuit claims Mereo omitted adverse facts indicating that neither Phase 3 study was hitting its primary endpoint of fracture reduction (www.globenewswire.com).

The worst-case scenario materialized on December 29, 2025: Mereo announced that neither ORBIT nor COSMIC met the primary endpoint (reduction in annualized fracture rate vs. placebo or standard of care), even though both studies did show significant improvements in bone mineral density (www.biospace.com). The stock collapsed – plunging from $2.31 on Dec 26 to just $0.29 on Dec 29, a crash of 87.7% in value (www.globenewswire.com). In the aftermath, numerous shareholder rights law firms (Rosen, Robbins LLP, etc.) have publicized calls for investors to join class-action suits. These suits broadly allege that Mereo misled investors by overhyping expected trial success while concealing the true risk of failure (www.globenewswire.com). Investors who suffered losses are encouraged to seek counsel promptly – the lead plaintiff filing deadline is April 6, 2026 (www.globenewswire.com), after which eligible shareholders may lose the chance to recover damages. In short, the legal overhang is now a major concern and a call to action for MREO investors.

Dividend Policy & Shareholder Yield

Mereo does not pay any dividend and has no history of shareholder distributions. The company’s official policy is to retain all funds to reinvest in R&D and growth, and it has “never paid or declared any cash dividends … and does not anticipate paying any … in the foreseeable future.” (www.sec.gov) This stance is common for clinical-stage biotech firms, which typically operate at a net loss and prioritize funding drug development over returning cash to shareholders. Indeed, under UK law Mereo cannot pay dividends until it has sufficient distributable profits, and as of the latest reports it has accumulated substantial losses (negative retained earnings) from years of intensive R&D spending (www.sec.gov). As a result, MREO’s dividend yield is 0%, and investors in the stock are relying entirely on capital gains potential (from successful drug approvals or partnerships) rather than income. Metrics like FFO/AFFO – used to evaluate dividend coverage for REITs – are not applicable here, given Mereo’s lack of steady operating cash flows and its focus on drug pipeline value rather than current earnings.

Financial Position, Leverage & Debt Maturities

One relative bright spot for Mereo is its balance sheet flexibility and low leverage. The company has no traditional long-term debt outstanding – an important factor as it weathers the post-trial fallout. Historically, Mereo raised capital through equity issuances and convertible loan notes (including a note issued to Novartis in 2020), rather than bank loans (www.sec.gov) (www.sec.gov). As of early 2025, those convertible notes have effectively been eliminated via conversion to equity: Mereo reported no remaining convertible debt on its books by Q1 2025, down from about $5.5 million (current portion) at the end of 2024 (www.mereobiopharma.com). The removal of these obligations means no imminent debt maturities or interest payments will pressure the company’s cash in the near term. In fact, Mereo even fully repaid a prior credit facility in late 2020, leaving it largely debt-free going forward (www.sec.gov).

Don't wait — first dividend checks could arrive any day.

Get the concise guide to start collecting royalty checks now.

Get Instant Access
✕

Liquidity: Mereo’s cash reserves are substantial relative to its burn rate, thanks in part to partnering and cost management. At the end of Q3 2025 (just before the trial result), the company held $48.7 million in cash – funds which, according to management, were expected to “support operations into 2027” (www.biospace.com). Crucially, Mereo’s collaboration with Ultragenyx on setrusumab helped defray expenses: Ultragenyx funded the global Phase 3 development of setrusumab (www.biospace.com), which allowed Mereo to conserve cash for other uses. After the December 2025 trial failure, Mereo swiftly cut discretionary spending (such as pre-commercial manufacturing for setrusumab) to extend its runway. The year-end 2025 cash balance was approximately $41 million, and updated guidance now projects that cash can fund operations through mid-2027 (www.biospace.com). Management noted that belt-tightening on the OI program “extended our cash runway to mid-2027” and affirmed a commitment to “tightly manage our resources” amid reassessing next steps (www.biospace.com).

With virtually no debt and a multi-year cash runway, Mereo currently has the capacity to meet its short-term obligations and continue baseline operations. Traditional leverage ratios and interest coverage metrics are essentially moot – interest expense is minimal, and the company’s coverage of operating costs comes largely from its cash reserves and any partner funding rather than internal cash flows (since it remains pre-revenue). It’s worth noting that further development of Mereo’s pipeline (especially the planned Phase 3 trial of alvelestat) will likely require external financing or partnerships. The absence of recurring revenue means that, once the existing cash is expended, Mereo would need to either raise capital (diluting shareholders) or secure a licensing deal to fund late-stage trials. In summary, solvency is not an immediate concern, but long-term funding for growth is an ongoing challenge – typical for a biotech in this stage.

Valuation and Stock Performance

In the wake of the trial disappointment, MREO’s market valuation has been brutally reset. The stock currently trades around $0.40 per share (USD) – a fraction of its price before the Phase 3 results were revealed (intellectia.ai). This implies a market capitalization on the order of ~$60–70 million (at ~$0.40 × ~159 million ADS equivalents outstanding), only slightly above the company’s net cash position. In other words, the market is now valuing Mereo largely for its liquidation value (cash on hand), assigning only a modest premium (if any) for the remaining pipeline. By comparison, as recently as late December 2025, MREO was trading above $2.30, before collapsing over 85% on the trial news (www.globenewswire.com). The stock’s violent decline reflects a loss of investor confidence in Mereo’s flagship asset and a recognition that future prospects are uncertain. It also puts Mereo in penny-stock territory, raising the risk of non-compliance with Nasdaq’s $1 minimum bid price listing rule (which could eventually force a reverse stock split if the price doesn’t recover).

Traditional valuation multiples like P/E or EV/EBITDA are not meaningful for Mereo, since the company has no earnings (reporting net losses, e.g. a $7.0 million net loss in Q3 2025 alone (www.biospace.com)). Even looking at price-to-book, MREO trades near 1.0× book value – with shareholders’ equity around $ Fifty-some million – indicating that the stock is priced almost at the value of its assets (mainly cash). This depressed valuation suggests the market assigns little credit to Mereo’s drug candidates at present, likely due to the high risk and extended timelines. Funds From Operations (FFO) metrics aren’t applicable, but effectively the company’s enterprise value (market cap minus cash) has shrunk to nearly the same magnitude as its contingent liabilities and R&D commitments.

Despite the grim market sentiment, it’s notable that Wall Street analysts have not entirely abandoned Mereo’s upside potential. According to recent analyst consensus, there are no “Sell” ratings on the stock; several analysts still rate it a Buy/Overweight, and the average price target is around $2.00+ per share (intellectia.ai) – which is many multiples above the current price. For example, the day after the trial failure, Cantor Fitzgerald’s analyst cut her target price from $6 to $3, yet maintained an Overweight rating on MREO (intellectia.ai). This stance implies that, in analysts’ view, Mereo’s remaining pipeline and assets could still justify a valuation several times higher than today’s price, if management can salvage value (through either new trial strategies, partnerships, or other strategic moves). However, these bullish targets should be taken with caution – they hinge on successful outcomes that are far from guaranteed (such as positive progress with alvelestat or a regulatory path forward for setrusumab’s bone density results). The stark gap between the stock’s trading price and analyst targets highlights the uncertainty and risk premium now baked into MREO: investors are clearly in “wait-and-see” mode, discounting the company heavily until clearer signs of value emerge.

Key Risks and Red Flags

Mereo faces heightened risks and multiple red flags following recent events:

– Securities Litigation & Credibility Risk: The ongoing class-action lawsuits themselves are a red flag regarding management’s credibility and disclosure practices. The suits allege that Mereo misrepresented clinical prospects, which, if proven, not only could lead to financial penalties but also tarnish management’s trustworthiness in the eyes of investors (www.globenewswire.com). Even if the company contests these claims, the proceedings can distract leadership and consume resources. Settling such suits often involves costly payouts (though likely covered in part by insurance) and can prompt governance changes. The mere existence of the litigation indicates that a segment of shareholders feels materially misled – an assertion that current and future investors must weigh seriously.

– Clinical Pipeline Concentration: Mereo’s fortunes have been heavily tied to setrusumab. The failure of both Phase 3 studies to meet their primary endpoints is a severe blow. While setrusumab did show benefit on bone density, fracture reduction was the key efficacy measure for approval – not achieving it greatly diminishes the drug’s approval likelihood or commercial value. There is a chance that further data analysis or discussions with regulators could find a path forward (for example, using bone density as a surrogate endpoint in a subset of patients), but this is speculative. At present, setrusumab’s outlook is murky, representing a major risk that what was once the lead asset may never generate returns after significant investment. This outcome also casts doubt on management’s prior optimistic assessments, reinforcing the credibility concerns.

– Reliance on a Single Major Partner: The setrusumab program is partnered with Ultragenyx, which has been co-developing (and funding) it. If Ultragenyx decides to withdraw support in light of the failed endpoints, Mereo would be left without the resources to continue that program alone. The partnership’s future is uncertain now – a significant risk since Ultragenyx’s commitment (or lack thereof) will determine if setrusumab sees any further trials. Losing this partner would effectively end the program and erase whatever contingent value remained.

– Early-Stage Pipeline & Development Risk: Beyond setrusumab, Mereo’s next most advanced candidate is alvelestat for alpha-1 antitrypsin deficiency-related lung disease. Alvelestat is Phase 3-ready but still unproven: it will require a large, lengthy pivotal trial (roughly 220 patients over 18 months, per plans) (www.biospace.com). Mereo is actively seeking a development/commercial partner for alvelestat (www.biospace.com), which is prudent given the company’s limited capital. However, there is a risk that no attractive partnership materializes promptly. Without a partner, Mereo might have to postpone the Phase 3 or attempt a smaller-scale study, neither of which is ideal. Even with sufficient funding, the trial itself carries typical clinical risk – there’s no guarantee alvelestat will meet its endpoints or gain approval, especially since no oral therapy for this condition has yet been approved (reflecting the difficulty of the target). In short, Mereo’s pipeline is now narrower and its success hinges on fewer shots on goal – a risky position.

– Nasdaq Compliance and Liquidity: The stock’s plunge into the sub-$1 range raises a red flag regarding market perception and listing status. Penny-stock levels could lead to lower liquidity and a loss of institutional investor interest (many funds cannot hold stocks under $5 or $1). Additionally, Mereo may receive a Nasdaq notice for failing to maintain a $1 share price. Typically, the company would have a 180-day grace period to rectify this (e.g. via a rebound or a reverse stock split). A forced reverse split to cure the deficiency is a risk – such actions can sometimes further erode value if not accompanied by fundamental improvement, as they may signal desperation and can invite short-selling pressure. Investors should watch for any communications about listing compliance.

– Historical Governance Concerns: It’s worth noting that even before the current crisis, activist shareholders had raised concerns about Mereo’s direction. In late 2022, Rubric Capital (a major shareholder) engaged in a proxy contest, which was resolved via a cooperation agreement that gave Rubric representation on Mereo’s board (www.sec.gov). The presence of an activist and the need for a board shake-up signaled underlying dissatisfaction with the company’s strategy or performance. Now, with the setback in OI and the stock at new lows, there is a heightened risk of renewed activist pressure. Large shareholders might push for strategic alternatives – for example, restructuring, asset sales, or even exploring a merger or sale of the company – if they have lost faith in the current plan. Such activism could be double-edged: it might catalyze positive change, or it could lead to disruptive boardroom battles. Either way, it emphasizes that governance and strategic direction are under the microscope.

– Potential Need for Dilution: While Mereo’s cash runway extends into mid-2027 on paper, that assumes a relatively austere operating plan. Should the company decide (or be forced) to finance a new trial or legal settlement out-of-pocket, the cash burn would accelerate. There is a risk of equity dilution if Mereo raises capital again. Any share issuance at the current low valuation would be very dilutive to existing shareholders. This risk is somewhat mitigated in the near term by management’s stated cash conservation and the hope of partnering to shoulder development costs. But if those plans fall through, dilution could return as a looming threat.

In sum, Mereo’s risk profile has dramatically escalated. The combination of legal, clinical, financial, and governance risks creates a challenging environment for investors. The company must navigate these minefields carefully to rebuild confidence.

Open Questions and Outlook

Given the uncertainty, investors are left with several open questions about Mereo’s future:

– Can the setrusumab program be salvaged at all? Management has not outright abandoned setrusumab; instead, they are conducting further analyses of the Phase 3 data to determine a potential path forward (www.biospace.com). There are hints that improvements in bone mineral density and reductions in fracture rate among certain patient subgroups (e.g. younger children in the COSMIC study) could be meaningful, albeit statistically inconclusive (www.biospace.com). Mereo, along with Ultragenyx, plans to “assess the totality of the data” and discuss with regulators what, if anything, can be done (www.biospace.com). One open question is whether regulators might consider BMD improvement as a basis for approval (perhaps under an unmet need scenario, given there are no approved treatments for OI (www.biospace.com)). This would be unusual without fracture reduction, but in Europe especially, there may be some flexibility if the data show trends toward benefit in a high-need pediatric population. Alternatively, could a new trial be designed focusing on a different endpoint or patient group? If so, who would fund it? Ultragenyx’s continued involvement is uncertain – will they pivot the trial design or decide the opportunity is not worth further investment? The answers to these questions will determine whether setrusumab retains any value or essentially becomes a write-off. Investors should watch for updates at scientific meetings (Mereo indicated data would be presented at the J.P. Morgan Healthcare Conference in Jan 2026 (www.biospace.com)) and any guidance from regulatory agencies on OI endpoints.

– What is the game plan for alvelestat? Alvelestat now becomes the centerpiece of Mereo’s pipeline, so its progress (or lack thereof) is critical. The company has aligned with FDA and EMA on a Phase 3 trial design and endpoints (www.mereobiopharma.com) (www.mereobiopharma.com), which is ready to launch. The big question is when and with whom. Management has been actively engaging potential partners for alvelestat (www.mereobiopharma.com), as developing it solo would likely exhaust Mereo’s resources. An open question is whether a partnership deal can be secured in 2026 – and on what terms. Any such deal could be a major catalyst (positive, if it provides non-dilutive funding and validates alvelestat’s promise; or negative, if terms are very dilutive or if no deal happens at all). Additionally, if a partner is found, will the trial start promptly? Or might it await the outcome of class-action distractions? Another consideration: the competitive landscape for AATD is evolving (e.g. gene therapies and other novel approaches are in development at larger firms). How well can alvelestat differentiate itself and attract a partner in this context? This remains an open question that will heavily influence Mereo’s value proposition in the coming year.

– How will the class-action lawsuits resolve? While not directly a matter of company operations, the outcome of the litigation is important to shareholders. Will Mereo fight the allegations or move toward a settlement? And if a settlement occurs, will it be covered by insurance or will the company need to pay out (which could impact its cash reserves)? Typically, these cases take time – possibly years – to resolve. A near-term unknown is who will be the lead plaintiff (the deadline for lead-plaintiff motions is April 6, 2026 (www.globenewswire.com)). A strong institutional lead plaintiff could intensify pressure on Mereo, whereas a smaller lead might be more amenable to a modest settlement. The reputation of Mereo’s management is also on the line; even without admitting guilt, the company may need to implement enhancements in disclosure or governance as part of a resolution. Investors will want to see how Mereo addresses the core issues raised: Was the communication around trial expectations overly bullish, and how will they ensure more transparency going forward? The lack of a certified class yet means it is early, but these questions will linger in investors’ minds as the case progresses.

– Will there be strategic changes (M&A or restructuring)? Now that Mereo’s market cap has shrunk and its lead asset stumbled, is the company a takeover target or ripe for consolidation? Larger pharma companies might find Mereo’s remaining assets (like alvelestat or the two oncology compounds in its portfolio) attractive at a bargain price – especially if management is under pressure. It’s conceivable that, rather than raise money to go it alone, Mereo could explore a sale or merger to maximize shareholder value. Recall that in 2019 Mereo itself merged with OncoMed Pharmaceuticals, acquiring some oncology assets. Today, given the tough spot, an inverse situation could occur where Mereo becomes the junior partner in a merger. Activist investors like Rubric might push for exploring these options if they believe the current team cannot deliver a turnaround. This is an open question: Will Mereo attempt to stay independent and rebuild, or seek an exit? So far, management has not publicly indicated any intent to pursue M&A, but the pressure from shareholders could change that, especially if the stock remains depressed.

– How will the Nasdaq listing issue be handled? If MREO’s share price does not naturally recover above $1, the company will have to address the Nasdaq compliance issue. An open question is when and how they will do so. They might bet on some positive catalyst (e.g. a partnership announcement) lifting the stock organically. If not, a reverse stock split (for example, combining shares at a 1-for-5 or 1-for-10 ratio) might be implemented in 2026 to bolster the price. Such corporate actions can affect investor perception and liquidity, so it’s worth monitoring. Management’s approach to this problem will signal their confidence (or lack thereof) in near-term fundamental improvements.

In conclusion, Mereo BioPharma’s situation is at a critical juncture. The company is financially stable in the short run but must navigate the fallout from a major clinical failure and the ensuing legal battles. The next few quarters will likely bring clarity on setrusumab’s fate (salvageable or not), the prospects of an alvelestat partnership, and the resolution of shareholder litigation. Investors should stay vigilant: developments on any of these fronts could significantly alter MREO’s risk/reward profile. Given the stakes, those who incurred heavy losses may indeed want to “act now” in evaluating their legal options – the window to join the class action as a lead plaintiff closes on April 6, 2026 (www.globenewswire.com) – while remaining alert to the strategic moves Mereo’s management will undertake to restore shareholder value. The coming months will show whether Mereo can turn the page on this setback or if it will succumb to the pressures bearing down on it.

Sources:

1. MREO class action complaint summary and stock drop (Robbins LLP press release) (www.globenewswire.com) (www.globenewswire.com) 2. Mereo CEO’s statement of confidence before Phase 3 results (Q3 2025 earnings press release) (www.biospace.com) 3. Mereo dividend policy disclosure (2022 Annual Report, Form 20-F) (www.sec.gov) 4. Mereo balance sheet excerpts showing no debt (Q1 2025 financial results) (www.mereobiopharma.com) 5. Liquidity and cash runway updates (Mereo Q3 2025 and Jan 2026 corporate update) (www.biospace.com) (www.biospace.com) 6. Ultragenyx partnership funding information (Mereo Q3 2025 report) (www.biospace.com) 7. Analyst sentiment and price target (Intellectia analyst summary) (intellectia.ai) (intellectia.ai) 8. Class-action lead plaintiff deadline reminder (Robbins LLP press release) (www.globenewswire.com) 9. Activist investor cooperation agreement info (Mereo 20-F filing) (www.sec.gov) 10. Mereo post-trial update on next steps (Jan 2026 corporate update) (www.biospace.com) (www.biospace.com)

For informational purposes only; not investment advice.